TM5275 sodium

TargetMol
Product Code: TAR-T4255
Supplier: TargetMol
CodeSizePrice
TAR-T4255-1mg1mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4255-2mg2mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4255-5mg5mg£156.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4255-1mL1 mL * 10 mM (in DMSO)£181.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4255-10mg10mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4255-25mg25mg£301.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4255-50mg50mg£461.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4255-100mg100mg£629.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4255-500mg500mg£1,267.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
TM5275 is an inhibitor of plasminogen activator inhibitor 1 (PAI-1).
CAS:
1103926-82-4
Formula:
C28H27ClN3NaO5
Molecular Weight:
543.98
Pathway:
Metabolism
Purity:
0.9955
SMILES:
[Na+].[O-]C(=O)c1cc(Cl)ccc1NC(=O)COCC(=O)N1CCN(CC1)C(c1ccccc1)c1ccccc1
Target:
PAI-1

References

Yasui H, et al. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells. Thromb Res. 2013 Jul;132(1):100-5. Mashiko S, et al. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther. 2015;16(2):253-60. Izuhara Y, et al. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab. 2010 May;30(5):904-12. Liu Y, Shu L, Jiang X, et al.The development of nasal polyps involves early middle meatus mucous remodeling via TGF-?1 mediated PAI-1 reduction.Brazilian Journal of Otorhinolaryngology.2023